1. imminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team). 2. "do not attempt resuscitation" order in place. 3. any end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment. 4. history of a moderate/severe lung disorder requiring home-based oxygen therapy. 5. patient requiring ecmo, hemodialysis or hemofiltration at the time of treatment administration. 6. current diagnosis of pulmonary embolism. 7. active neoplasm, except carcinoma in situ or basalioma. 8. known allergy to the products involved in the allogenic msc production process. 9. current pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment). 10. current participation in a clinical trial with an experimental treatment for covid-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria). 11. any circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial.

1. imminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team). 2. "do not attempt resuscitation" order in place. 3. any end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment. 4. history of a moderate/severe lung disorder requiring home-based oxygen therapy. 5. patient requiring ecmo, hemodialysis or hemofiltration at the time of treatment administration. 6. current diagnosis of pulmonary embolism. 7. active neoplasm, except carcinoma in situ or basalioma. 8. known allergy to the products involved in the allogenic msc production process. 9. current pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment). 10. current participation in a clinical trial with an experimental treatment for covid-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria). 11. any circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial.

imminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team). "do not attempt resuscitation" order in place. any end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment. history of a moderate/severe lung disorder requiring home-based oxygen therapy. patient requiring ecmo, hemodialysis or hemofiltration at the time of treatment administration. current diagnosis of pulmonary embolism. active neoplasm, except carcinoma in situ or basalioma. known allergy to the products involved in the allogenic msc production process. current pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment). current participation in a clinical trial with an experimental treatment for covid-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria). any circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial.

imminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team). "do not attempt resuscitation" order in place. any end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment. history of a moderate/severe lung disorder requiring home-based oxygen therapy. patient requiring ecmo, hemodialysis or hemofiltration at the time of treatment administration. current diagnosis of pulmonary embolism. active neoplasm, except carcinoma in situ or basalioma. known allergy to the products involved in the allogenic msc production process. current pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment). current participation in a clinical trial with an experimental treatment for covid-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria). any circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial.

1. imminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team). 2. "do not attempt resuscitation" order in place. 3. any end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment. 4. history of a moderate/severe lung disorder requiring home-based oxygen therapy. 5. patient requiring ecmo, hemodialysis or hemofiltration at the time of treatment administration. 6. current diagnosis of pulmonary embolism. 7. active neoplasm, except carcinoma in situ or basalioma. 8. known allergy to the products involved in the allogenic msc production process. 9. current pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment). 10. current participation in a clinical trial with an experimental treatment for covid-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria). 11. any circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial.

1. imminent and unavoidable progression to death within 24 hours, irrespective of the provision of treatments (in the opinion of the clinical team). 2. "do not attempt resuscitation" order in place. 3. any end-stage organ disease or condition, which in the investigator's opinion, makes the patient an unsuitable candidate for treatment. 4. history of a moderate/severe lung disorder requiring home-based oxygen therapy. 5. patient requiring ecmo, hemodialysis or hemofiltration at the time of treatment administration. 6. current diagnosis of pulmonary embolism. 7. active neoplasm, except carcinoma in situ or basalioma. 8. known allergy to the products involved in the allogenic msc production process. 9. current pregnancy or lactation (women with childbearing potential should have a negative pregnancy test result at the time of study enrollment). 10. current participation in a clinical trial with an experimental treatment for covid-19 (the use of any off-label medicine according to local treatment protocols is not an exclusion criteria). 11. any circumstances that in the investigator's opinion compromises the patient's ability to participate in the clinical trial.